Fig. 2: Murine ILC2s constitutively express CD52, and this expression is inducible by IL-33. | Mucosal Immunology

Fig. 2: Murine ILC2s constitutively express CD52, and this expression is inducible by IL-33.

From: CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation

Fig. 2

a A group of WT mice (n = 6 mice) was challenged with recombinant mouse (rm)-IL-33 (0.5 µg in 50 µL) or PBS intranasally (i.n.) on days 1, 2, and 3. The mice were euthanized on day 4 and the lung was isolated, as shown in the timeline. b The gating strategy of ILC2s identified as Lin–CD45+CD127+ST2+ cells. c, d mRNA and protein expression levels of CD52 in both naïve (PBS) and IL-33-activated ILC2s in the lungs. Corresponding FACS quantitation of CD52 expression shown as MFI ± SEM, n = 6 mice. mRNA levels obtained from n = 2–3 mice. e Naïve pulmonary ILC2s were sorted (n = 6 mice) and subsequently cultured with rm-IL-2 and rm-IL-7 and rm-IL-33 for 12, 24, and 48 h. Freshly isolated ILC2s at 0 h and ex vivo activated ILC2s were analyzed by flow cytometry as indicated in the scheme and the kinetics of CD52 induction by IL-33 is shown. Statistical analysis, two-tailed Student’s t-test or one-way ANOVA followed by Tukey post-hoc tests. **P < 0.01, ***P < 0.001. Mouse and lung images are provided with permission from Servier Medical Art.

Back to article page